DLA Troop Support issued an RFI seeking sources capable of supplying the FDA-licensed Antidote Treatment Nerve Agent Auto-Injector (ATNAA), made in accordance with MPID Number 6 dated May 2, 2019. The auto-injector must deliver 2.1 mg atropine and 600 mg pralidoxime chloride in separate chambers for intramuscular administration, and firms must have FDA approval to sell it. Manufacturers or distributors are asked to provide place of manufacture, estimated annual capacity, FDA registration, product details, current unit sale price, and inventory/storage requirements. Firms with products under development are also invited to describe development stage and any independent laboratory or FDA testing/trials. Responses will inform DLA Troop Support’s planning and procurement strategy and should be sent electronically to the contracting officer, Jessica De La Hoz.